RGD胜肽市場按應用、最終用途、類型、形式和分子量分類，全球預測（2026-2032年）

RGD胜肽市場預計到2025年將達到2.6848億美元，到2026年將成長到2.9955億美元，到2032年將達到5.2545億美元，複合年成長率為10.06%。

關鍵市場統計數據
基準年 2025	2.6848億美元
預計年份：2026年	2.9955億美元
預測年份 2032	5.2545億美元
複合年成長率 (%)	10.06%

本書權威地介紹了RGD胜肽的生化作用、關鍵的轉化聯繫，以及為何相關人員應優先考慮對其策略理解。

本報告對RGD胜肽進行了清晰權威的闡述，介紹了其在細胞黏附中的生化作用，以及其對研究和商業應用的重要策略意義。 RGD胜肽是由整合素受體辨識的短胺基酸序列，是細胞-基質相互作用的重要介質，並在研究分析和生物醫學應用解決方案中發揮模組化配體的作用。理解RGD基序的基本生物學特性至關重要，因為其相互作用的動態變化會影響分析設計、表面修飾、標靶遞送系統以及組織支架的表現。

關鍵的技術、監管和供應鏈力量正在匯聚，重塑 RGD 胜肽在多學科領域的開發、檢驗和商業化。

胜肽工程、表面科學和轉化生物學領域的融合進展正在加速從發現到應用的進程，並改變RGD肽的模式。化學選擇性合成技術的進步，包括改進的環化方法和位點特異性修飾，提高了配體的穩定性和整合素選擇性，在體外實驗和裝置介面中實現了更可靠的性能。同時，高解析度質譜和表面等離子體共振等分析表徵技術的進步，增強了人們對結構-功能關係的信心，並使研究團隊能夠更快地迭代設計，減少實驗次數。

評估不斷變化的美國關稅措施對胜肽類藥物研發領域的採購、供應商策略和業務永續營運的影響

近期貿易政策的變化給依賴國際採購原料、契約製造和實驗室試劑的企業帶來了新的成本和營運方面的挑戰。關稅措施及相關的非關稅應對措施會改變供應商的經濟狀況，迫使採購方重新評估供應商合格框架，並要求制定入境物流緊急時應對計畫，從而增加採購營運的複雜性。在依賴胜肽的工作流程中，試劑純度和批次間性能的一致性至關重要，即使是輕微的干擾和成本波動也可能導致檢驗工作量增加，並延長檢測方法驗證和設備開發時間。

透過綜合分析應用需求、最終用途要求、分子類型、供應形式和分子量等因素，為策略決策提供支援。

分段觀點突顯了技術需求與商業性優先事項的分歧領域，以及能夠帶來最大回報的定向投資領域。縱觀細胞黏附研究、診斷檢測、藥物遞送、醫療設備塗層和組織工程等多種應用，每種應用場景都提出了獨特的性能和監管要求，這些要求會影響胜肽的設計方案和檢驗路徑。細胞黏附實驗強調可重複性和表面呈現，而診斷檢測則優先考慮特異性和批間一致性。藥物遞送應用需要控釋和生物穩定性，而器械塗層則要求耐久性和符合監管要求的生物相容性。組織工程應用則著重於支架整合和長期細胞反應。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和促進因素將影響RGD胜肽相關計劃的採納、採購和監管協調。

區域趨勢在塑造胜肽類技術的監管要求、供應商生態系統和應用路徑方面發揮著至關重要的作用。在美洲，成熟的研究基礎設施、廣泛的合約組織網路以及開放的商業生態系統促進了早期應用，並推動了開發商和買家之間的密切合作。監管和津貼計畫也支持轉化研究，從而加速從概念驗證研究到臨床試驗材料的轉化。

競爭格局與企業趨勢：建立專業知識、夥伴關係和品質能力將如何重新定義胜肽解決方案領域的領導地位

胜肽領域的企業活動呈現出專業化、策略聯盟和多層次能力並存的特徵。胜肽合成專家正致力於投資基礎化學和品質體系，以提高重現性並降低雜質含量；而診斷和醫療設備公司則將胜肽專業知識整合到更廣泛的產品系列中，以增強表面功能和標靶化能力。合約開發和生產組織（CDMO）正在拓展其服務範圍，包括法規支援、分析開發和可擴展的胜肽生產，以滿足早期開發商和大規模商業合作夥伴的需求。

為領導者提供切實可行的優先步驟，以增強韌性、最佳化發展路徑，並將RGD胜肽創新成果快速轉化為應用解決方案。

為了將科學優勢轉化為永續的商業性和營運成果，領導者應優先採取一系列切實可行的措施，使技術能力與供應鏈韌性和監管準備保持一致。首先，將可製造性和供應商選擇納入早期開發規劃，使胜肽設計從一開始就考慮規模限制和品質規格。這可以減少後續迭代，並有助於在產品過渡到受監管環境時進行驗證。其次，實現供應商關係的地理多元化，並至少認證一個關鍵投入的區域供應商，以降低貿易政策和物流中斷的影響。

一份透明的調查方法說明，清楚地概述了文獻綜述、專家對話、分析框架和檢驗方法，以支持報告的結論。

研究途徑結合了對同儕審查文獻、技術白皮書和已發布的監管指南的系統性回顧，以及對專家和從業人員的定性訪談。我們利用二手資料梳理了胜肽化學、分析方法和供應鏈結構的歷史發展趨勢，並透過訪談深入了解了採購行為、檢驗重點和風險管理實務等方面的背景資訊。分析架構包括一項比較技術評估，用於評估環狀、線性和修飾RGD結構之間的設計權衡；以及一項供應鏈映射，用於識別單一來源的薄弱環節和區域優勢。

透過對科學進展、實際操作情況和政策因素進行綜合分析，可以為參與胜肽類藥物主導措施的相關人員提供清晰的策略啟示。

這項綜合分析凸顯了一個明確的需求：將RGD胜肽已證實的生物效用轉化為可靠、符合法規且具有商業性可行性的應用，需要化學、分析、供應鏈和法規規劃等各環節的協調投資。儘管胜肽設計方面的科學進步降低了穩定性和特異性方面的傳統障礙，但供應商選擇標準、區域法規差異以及貿易相關波動等營運和政策因素，如今對專案執行進度和風險狀況的影響卻不成比例地更大。能夠將技術選擇與切實可行的採購、品質和法規策略相結合的企業將取得最大的成功。

目錄

第1章：序言

第2章調查方法

• 研究設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查前提
• 調查限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會地圖
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. RGD肽市場依應用領域分類

• 細胞黏附研究
• 診斷檢測
• 藥物遞送
• 醫療設備塗層
• 組織工程

9. RGD肽市場依最終用途分類

• 學術研究
• 生物技術
• 診斷
• 製藥

第10章：RGD胜肽市場（按類型分類）

• 圓
• 線性類型
• 合格類型

第11章：RGD胜肽市場（依形式分類）

• 凍乾產品
• 粉末
• 解決方案

12. RGD肽市場（以分子量分類）

• 高分子量
• 低分子量
• 中等分子量

第13章：RGD胜肽市場區域分析

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章 RGD胜肽市場（依組別分類）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章 各國RGD胜肽市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章：美國RGD胜肽市場

第17章：中國的RGD胜肽市場

第18章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• AmbioPharm, Inc.
• AnaSpec Inc.
• Bachem Holding AG
• Bio-Synthesis, Inc.
• Biomatik Corporation
• Biotage AB
• CEM Corporation
• Corden Pharma GmbH
• CPC Scientific Inc.
• Creative Peptides
• CSBio Company, Inc.
• GenScript Biotech Corporation
• GL Biochem（Shanghai）Ltd.
• Hybio Pharmaceutical Co. Ltd.
• JPT Peptide Technologies
• Merck KGaA
• New England Peptide, Inc.
• Peptides International, LLC
• PolyPeptide Group
• ProteoGenix
• Scilight-Peptide Inc.
• SynPeptide Co., Ltd.
• Thermo Fisher Scientific Inc.
• USV Private Limited
• WuXi AppTec

The RGD Peptide Market was valued at USD 268.48 million in 2025 and is projected to grow to USD 299.55 million in 2026, with a CAGR of 10.06%, reaching USD 525.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 268.48 million
Estimated Year [2026]	USD 299.55 million
Forecast Year [2032]	USD 525.45 million
CAGR (%)	10.06%

An authoritative primer explaining the biochemical role of RGD peptides, key translational linkages, and why stakeholders should prioritize strategic understanding

This executive dossier provides a clear and authoritative orientation to RGD peptides, their biochemical role in cell adhesion, and their strategic relevance across research and commercial domains. RGD peptides are short amino acid sequences recognized by integrin receptors, serving as key mediators of cell-matrix interactions and functioning as modular ligands in both investigative assays and applied biomedical solutions. Understanding the fundamental biology of RGD motifs is essential because their interaction dynamics influence assay design, surface engineering, targeted delivery systems, and tissue scaffold performance.

Beyond molecular function, RGD peptides occupy a unique translational nexus where basic science informs applied engineering and clinical development. Their utility spans laboratory-focused cell adhesion models, diagnostic assay platforms that exploit integrin binding, and biomedical product coatings that modulate host responses. The introduction sets the stage for a deeper review by clarifying terminology, delineating principal applications, and framing the consequential linkages between scientific advances and operational considerations that follow in subsequent sections.

Key technological, regulatory, and supply chain forces converging to reshape how RGD peptides are developed, validated, and commercialized across disciplines

The RGD peptide landscape is being transformed by convergent advances in peptide engineering, surface science, and translational biology that are accelerating the pace from discovery to applied use. Advances in chemoselective synthesis, including improved methods for cyclization and site-specific modification, have enhanced ligand stability and integrin selectivity, enabling more reliable performance in both in vitro assays and device interfaces. Concurrent improvements in analytical characterization-high-resolution mass spectrometry and surface plasmon resonance-have increased confidence in structure-function relationships, allowing teams to iterate designs more rapidly and with fewer experimental cycles.

At the same time, cross-disciplinary pressures are reshaping adoption pathways. Regulatory authorities are placing greater emphasis on biocompatibility testing and transparency in sourcing, which is prompting earlier incorporation of manufacturability and regulatory alignment into development plans. Meanwhile, the proliferation of contract development and manufacturing partnerships is enabling smaller innovators to scale peptide-enabled solutions without extensive in-house infrastructure. Taken together, these technological and structural shifts are driving a landscape where scientific rigor, supply chain maturity, and regulatory foresight determine the speed and success of translation from bench to application.

Evaluating how evolving United States tariff measures can affect procurement, supplier strategies, and operational continuity for peptide-dependent research and development

Recent trade policy dynamics have introduced new cost and operational considerations for organizations that rely on internationally sourced raw materials, contract manufacturing, and laboratory reagents. Tariff measures and associated non-tariff responses can amplify procurement complexity by altering supplier economics, forcing buyers to re-evaluate supplier qualification frameworks, and requiring contingency planning for inbound logistics. For peptide-dependent workflows, where reagent purity and consistent lot-to-lot performance are critical, even modest disruptions or cost variances can translate into increased validation burdens and extended timelines for assay qualification and device development.

In response, many stakeholders are adapting sourcing strategies to mitigate exposure and preserve program momentum. Tactical responses include diversifying supplier networks across geographies, prioritizing qualified domestic or regional suppliers for critical inputs, and increasing inventory buffers for long-lead items. Process optimization and closer collaboration with suppliers on quality systems can reduce the operational friction introduced by tariff-induced supplier changes. Overall, the cumulative effect of tariff-driven disruptions emphasizes the importance of supply chain visibility, flexible procurement policies, and early supplier engagement to maintain continuity in research and product development activities.

Integrated segmentation analysis connecting application needs, end-use requirements, molecular types, supply formats, and molecular weight considerations to inform strategic decisions

A segmentation-informed perspective clarifies where technical needs and commercial priorities diverge and where targeted investments will yield the highest return. When looking across applications such as cell adhesion studies, diagnostic assays, drug delivery, medical device coatings, and tissue engineering, each use case imposes distinct performance and regulatory requirements that influence peptide design choices and validation pathways. Cell adhesion experiments emphasize reproducibility and surface presentation, diagnostic assays prioritize specificity and batch consistency, drug delivery applications require controlled release and biostability, device coatings demand durability and regulatory-grade biocompatibility, and tissue engineering applications focus on scaffold integration and long-term cellular responses.

End-use contexts including academic research, biotechnology, diagnostic, and pharmaceutical settings further shape priorities around documentation, lot traceability, and supply continuity. From a product-type perspective, cyclic, linear, and modified RGD constructs offer trade-offs between conformational stability and synthetic tractability, guiding selection based on intended function. The physical form of supply-whether lyophilized, powder, or solution-affects shelf life, shipping constraints, and downstream handling, while molecular weight distinctions among high, medium, and low molecular weight variants inform diffusion behavior, surface density considerations, and pharmacokinetic expectations. Synthesizing these dimensions highlights how technical, regulatory, and operational vectors must be aligned to match the right peptide configuration to its target application and stakeholder requirements.

Regional dynamics and enablers across Americas, Europe, Middle East & Africa, and Asia-Pacific that influence adoption, sourcing, and regulatory alignment for RGD peptide initiatives

Regional dynamics play a decisive role in shaping regulatory expectations, supplier ecosystems, and adoption trajectories for peptide-enabled technologies. In the Americas, a mature research infrastructure, a deep network of contract organizations, and a receptive commercial ecosystem drive early adoption and close collaboration between developers and purchasers. Regulatory agencies and grant mechanisms also support translational initiatives that can accelerate the movement from proof-of-concept work to clinical trial material.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and strong academic-industrial partnerships foster rigorous evaluation of biocompatibility and safety, while localized manufacturing hubs contribute to resilient supply chains. In the Asia-Pacific region, rapid scale-up capabilities, competitive manufacturing, and robust reagent supply networks offer cost and capacity advantages, although stakeholders must navigate diverse regulatory pathways and varying standards for clinical translation. Understanding these regional attributes enables organizations to calibrate sourcing strategies, select appropriate regulatory engagement approaches, and identify strategic partners to support both immediate project needs and longer-term commercialization pathways.

Competitive landscape and corporate dynamics revealing how specialization, partnerships, and quality capability buildouts are redefining leadership in peptide solutions

Corporate activity in the peptide domain is characterized by a mix of specialization, strategic partnerships, and capability layering. Companies focused on peptide synthesis have invested in platform chemistries and quality systems to improve reproducibility and reduce impurity profiles, while diagnostic and device-oriented firms are integrating peptide expertise into broader product portfolios to enhance surface functionality and targeting. Contract development and manufacturing organizations are expanding services to include regulatory support, analytical development, and scalable peptide production to meet the needs of both early-stage developers and larger commercial partners.

Collaboration models-ranging from co-development agreements to manufacturing partnerships-are increasingly preferred over solitary approaches, as they enable sharing of risk and faster access to complementary capabilities. Investment in specialized analytical capacity and robust quality management systems signals which organizations are best positioned to supply regulated applications. For stakeholders selecting partners, emphasis should be placed on demonstrated technical depth, transparent quality evidence, and the ability to support lifecycle activities beyond initial supply, such as stability studies, change control, and regulatory documentation.

Practical, prioritized steps for leaders to strengthen resilience, optimize development pathways, and accelerate translation of RGD peptide innovations into applied solutions

To convert scientific advantage into durable commercial and operational outcomes, leaders should prioritize a set of practical actions that align technical performance with supply chain resilience and regulatory readiness. First, integrate manufacturability and supplier qualification into early development planning so peptide designs account for scale constraints and quality specifications from the outset. This reduces iteration later and facilitates smoother validation when moving to regulated contexts. Second, diversify supplier relationships geographically while qualifying at least one regional source for critical inputs to mitigate trade-policy and logistical disruptions.

Third, invest in analytical and process characterization capabilities that enable rapid troubleshooting and reduce batch variability, complemented by transparent documentation practices that meet the expectations of diagnostic and pharmaceutical end users. Fourth, pursue strategic collaborations with contract organizations or academic partners to access specialized capabilities without the full capital investment of in-house expansion. Finally, embed regulatory strategy into program timelines, engaging with relevant authorities or notified bodies early to clarify biocompatibility expectations and streamline downstream approvals. Taken together, these actions strengthen resilience and accelerate the translation of RGD-enabled innovations into practice.

Transparent methodological description outlining literature synthesis, expert engagement, analytical frameworks, and validation practices that underpin the report's conclusions

The research approach combined a structured review of peer-reviewed literature, technical white papers, and publicly available regulatory guidance with primary qualitative interviews of domain experts and practitioners. Secondary sources were used to map historical trends in peptide chemistry, analytical practices, and supply chain configurations, while primary interviews provided contextual nuance on procurement behavior, validation priorities, and risk management approaches. Analytical frameworks included comparative technology assessment to evaluate design trade-offs among cyclic, linear, and modified RGD constructs and supply chain mapping to identify single-source vulnerabilities and regional strengths.

Data validation incorporated cross-referencing of interview insights against published experimental protocols and internal quality documents provided during engagement with consenting organizations. The methodological emphasis on triangulation and traceable evidence ensures that conclusions are supported by multiple independent lines of inquiry. Limitations are acknowledged where proprietary or nascent commercial data were unavailable, and recommendations are framed to be robust to variability in organizational scale and regulatory jurisdictional differences.

Concluding synthesis that connects scientific progress, operational realities, and policy factors to provide clear strategic takeaways for stakeholders in peptide-driven initiatives

The synthesis underscores a clear imperative: translating the proven biological utility of RGD peptides into reliable, regulated, and commercially viable applications requires coordinated investments across chemistry, analytics, supply chain, and regulatory planning. Scientific advances in peptide design have reduced historical barriers related to stability and specificity, but operational and policy variables - including supplier qualification, regional regulatory nuance, and trade-related volatility - now exert outsized influence on execution timelines and program risk profiles. Successful actors will be those who align technical choices with pragmatic sourcing, quality, and regulatory strategies.

Ultimately, the path forward favors interdisciplinary collaboration, early engagement with manufacturing and regulatory partners, and disciplined attention to analytical characterization and documentation. By aligning these elements with a clear segmentation and regional strategy, organizations can better position RGD peptide-enabled solutions for robust performance in both research and applied settings and reduce avoidable delays during critical development transitions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RGD Peptide Market, by Application

• 8.1. Cell Adhesion Studies
• 8.2. Diagnostic Assays
• 8.3. Drug Delivery
• 8.4. Medical Device Coatings
• 8.5. Tissue Engineering

9. RGD Peptide Market, by End Use

• 9.1. Academic Research
• 9.2. Biotechnology
• 9.3. Diagnostic
• 9.4. Pharmaceutical

10. RGD Peptide Market, by Type

• 10.1. Cyclic
• 10.2. Linear
• 10.3. Modified

11. RGD Peptide Market, by Form

• 11.1. Lyophilized
• 11.2. Powder
• 11.3. Solution

12. RGD Peptide Market, by Molecular Weight

• 12.1. High Molecular Weight
• 12.2. Low Molecular Weight
• 12.3. Medium Molecular Weight

13. RGD Peptide Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. RGD Peptide Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. RGD Peptide Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States RGD Peptide Market

17. China RGD Peptide Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. AmbioPharm, Inc.
• 18.6. AnaSpec Inc.
• 18.7. Bachem Holding AG
• 18.8. Bio-Synthesis, Inc.
• 18.9. Biomatik Corporation
• 18.10. Biotage AB
• 18.11. CEM Corporation
• 18.12. Corden Pharma GmbH
• 18.13. CPC Scientific Inc.
• 18.14. Creative Peptides
• 18.15. CSBio Company, Inc.
• 18.16. GenScript Biotech Corporation
• 18.17. GL Biochem (Shanghai) Ltd.
• 18.18. Hybio Pharmaceutical Co. Ltd.
• 18.19. JPT Peptide Technologies
• 18.20. Merck KGaA
• 18.21. New England Peptide, Inc.
• 18.22. Peptides International, LLC
• 18.23. PolyPeptide Group
• 18.24. ProteoGenix
• 18.25. Scilight-Peptide Inc.
• 18.26. SynPeptide Co., Ltd.
• 18.27. Thermo Fisher Scientific Inc.
• 18.28. USV Private Limited
• 18.29. WuXi AppTec

LIST OF FIGURES

• FIGURE 1. GLOBAL RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL RGD PEPTIDE MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL RGD PEPTIDE MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL RGD PEPTIDE MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL RGD PEPTIDE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL RGD PEPTIDE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL RGD PEPTIDE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL RGD PEPTIDE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL RGD PEPTIDE MARKET SIZE, BY CELL ADHESION STUDIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL RGD PEPTIDE MARKET SIZE, BY CELL ADHESION STUDIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL RGD PEPTIDE MARKET SIZE, BY CELL ADHESION STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC ASSAYS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL RGD PEPTIDE MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL RGD PEPTIDE MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL RGD PEPTIDE MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDICAL DEVICE COATINGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDICAL DEVICE COATINGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDICAL DEVICE COATINGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL RGD PEPTIDE MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL RGD PEPTIDE MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL RGD PEPTIDE MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL RGD PEPTIDE MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL RGD PEPTIDE MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL RGD PEPTIDE MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL RGD PEPTIDE MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL RGD PEPTIDE MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL RGD PEPTIDE MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL RGD PEPTIDE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL RGD PEPTIDE MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL RGD PEPTIDE MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL RGD PEPTIDE MARKET SIZE, BY CYCLIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL RGD PEPTIDE MARKET SIZE, BY CYCLIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL RGD PEPTIDE MARKET SIZE, BY CYCLIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL RGD PEPTIDE MARKET SIZE, BY LINEAR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL RGD PEPTIDE MARKET SIZE, BY LINEAR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL RGD PEPTIDE MARKET SIZE, BY LINEAR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL RGD PEPTIDE MARKET SIZE, BY MODIFIED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL RGD PEPTIDE MARKET SIZE, BY MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL RGD PEPTIDE MARKET SIZE, BY MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL RGD PEPTIDE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL RGD PEPTIDE MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL RGD PEPTIDE MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL RGD PEPTIDE MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL RGD PEPTIDE MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL RGD PEPTIDE MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL RGD PEPTIDE MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL RGD PEPTIDE MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL RGD PEPTIDE MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL RGD PEPTIDE MARKET SIZE, BY HIGH MOLECULAR WEIGHT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL RGD PEPTIDE MARKET SIZE, BY HIGH MOLECULAR WEIGHT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL RGD PEPTIDE MARKET SIZE, BY HIGH MOLECULAR WEIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL RGD PEPTIDE MARKET SIZE, BY LOW MOLECULAR WEIGHT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL RGD PEPTIDE MARKET SIZE, BY LOW MOLECULAR WEIGHT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL RGD PEPTIDE MARKET SIZE, BY LOW MOLECULAR WEIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDIUM MOLECULAR WEIGHT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDIUM MOLECULAR WEIGHT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDIUM MOLECULAR WEIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL RGD PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 62. AMERICAS RGD PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 63. AMERICAS RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 64. AMERICAS RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 65. AMERICAS RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 66. AMERICAS RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 67. AMERICAS RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 68. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 70. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 71. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 72. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 73. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 74. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 76. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 77. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 78. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 79. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 86. EUROPE RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 87. EUROPE RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 89. EUROPE RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 90. EUROPE RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 91. EUROPE RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 92. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 94. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 95. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 96. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 97. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 98. AFRICA RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. AFRICA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 100. AFRICA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 101. AFRICA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 102. AFRICA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 103. AFRICA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 104. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 105. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 106. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 107. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 108. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 109. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL RGD PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 111. ASEAN RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. ASEAN RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 113. ASEAN RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 114. ASEAN RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 115. ASEAN RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 116. ASEAN RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 117. GCC RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 118. GCC RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 119. GCC RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 120. GCC RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 121. GCC RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 122. GCC RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 123. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 124. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 125. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 126. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 127. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 128. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 129. BRICS RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. BRICS RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 131. BRICS RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 132. BRICS RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 133. BRICS RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 134. BRICS RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 135. G7 RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 136. G7 RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 137. G7 RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 138. G7 RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 139. G7 RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 140. G7 RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 141. NATO RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 142. NATO RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 143. NATO RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 144. NATO RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 145. NATO RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 146. NATO RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 147. GLOBAL RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 148. UNITED STATES RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 149. UNITED STATES RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 150. UNITED STATES RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 151. UNITED STATES RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 152. UNITED STATES RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 153. UNITED STATES RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 154. CHINA RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 155. CHINA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 156. CHINA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 157. CHINA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 158. CHINA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 159. CHINA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)